Four of six patients with neovascular age-related macular degeneration treated with a threefold lower dose of ADVM-022 in the OPTIC phase 1 trial did not require a rescue injection 24 weeks after treatment and demonstrated an efficacy signal with evidence of dose response.
David S. Boyer, MD, presented the first data from cohort two of the OPTIC trial at Bascom Palmer Eye Institute’s Angiogenesis, Exudation, and Degeneration 2020 symposium in Miami. The multicenter, open-label, dose-ranging trial is assessing the safety and tolerability of a single intravitreal injection of ADVM-022
Uncategorized